Cargando…
rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441347/ http://dx.doi.org/10.1186/1742-4690-9-S2-P132 |
| _version_ | 1782243267747774464 |
|---|---|
| author | Montefiori, DC Huang, Y Karuna, S Allen, M Kochar, N Chappuis, S Gaillard, J Tomaras, G Graham, B Bart, P Pantaleo, G |
| author_facet | Montefiori, DC Huang, Y Karuna, S Allen, M Kochar, N Chappuis, S Gaillard, J Tomaras, G Graham, B Bart, P Pantaleo, G |
| author_sort | Montefiori, DC |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3441347 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2012 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-34413472012-09-18 rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1 Montefiori, DC Huang, Y Karuna, S Allen, M Kochar, N Chappuis, S Gaillard, J Tomaras, G Graham, B Bart, P Pantaleo, G Retrovirology Poster Presentation BioMed Central 2012-09-13 /pmc/articles/PMC3441347/ http://dx.doi.org/10.1186/1742-4690-9-S2-P132 Text en Copyright ©2012 Montefiori et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Montefiori, DC Huang, Y Karuna, S Allen, M Kochar, N Chappuis, S Gaillard, J Tomaras, G Graham, B Bart, P Pantaleo, G rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1 |
| title | rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1 |
| title_full | rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1 |
| title_fullStr | rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1 |
| title_full_unstemmed | rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1 |
| title_short | rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1 |
| title_sort | rad5/nyvac-b is superior to nyvac-b/rad5 and is dependent on rad5 dose for neutralizing antibody responses against hiv-1 |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441347/ http://dx.doi.org/10.1186/1742-4690-9-S2-P132 |
| work_keys_str_mv | AT montefioridc rad5nyvacbissuperiortonyvacbrad5andisdependentonrad5doseforneutralizingantibodyresponsesagainsthiv1 AT huangy rad5nyvacbissuperiortonyvacbrad5andisdependentonrad5doseforneutralizingantibodyresponsesagainsthiv1 AT karunas rad5nyvacbissuperiortonyvacbrad5andisdependentonrad5doseforneutralizingantibodyresponsesagainsthiv1 AT allenm rad5nyvacbissuperiortonyvacbrad5andisdependentonrad5doseforneutralizingantibodyresponsesagainsthiv1 AT kocharn rad5nyvacbissuperiortonyvacbrad5andisdependentonrad5doseforneutralizingantibodyresponsesagainsthiv1 AT chappuiss rad5nyvacbissuperiortonyvacbrad5andisdependentonrad5doseforneutralizingantibodyresponsesagainsthiv1 AT gaillardj rad5nyvacbissuperiortonyvacbrad5andisdependentonrad5doseforneutralizingantibodyresponsesagainsthiv1 AT tomarasg rad5nyvacbissuperiortonyvacbrad5andisdependentonrad5doseforneutralizingantibodyresponsesagainsthiv1 AT grahamb rad5nyvacbissuperiortonyvacbrad5andisdependentonrad5doseforneutralizingantibodyresponsesagainsthiv1 AT bartp rad5nyvacbissuperiortonyvacbrad5andisdependentonrad5doseforneutralizingantibodyresponsesagainsthiv1 AT pantaleog rad5nyvacbissuperiortonyvacbrad5andisdependentonrad5doseforneutralizingantibodyresponsesagainsthiv1 |